pubmed-article:21301335 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:21301335 | lifeskim:mentions | umls-concept:C0021289 | lld:lifeskim |
pubmed-article:21301335 | lifeskim:mentions | umls-concept:C0023779 | lld:lifeskim |
pubmed-article:21301335 | lifeskim:mentions | umls-concept:C0002679 | lld:lifeskim |
pubmed-article:21301335 | lifeskim:mentions | umls-concept:C0008300 | lld:lifeskim |
pubmed-article:21301335 | lifeskim:mentions | umls-concept:C0086123 | lld:lifeskim |
pubmed-article:21301335 | lifeskim:mentions | umls-concept:C1708063 | lld:lifeskim |
pubmed-article:21301335 | lifeskim:mentions | umls-concept:C0524527 | lld:lifeskim |
pubmed-article:21301335 | pubmed:issue | 2 | lld:pubmed |
pubmed-article:21301335 | pubmed:dateCreated | 2011-2-24 | lld:pubmed |
pubmed-article:21301335 | pubmed:abstractText | The aim is to compare the available evidence on the efficacy and safety of deoxycholate and lipid amphotericin B formulations (AMBF) in the treatment of invasive fungal disease (IFD) in neonates. The review also aims to summarize current practices and recommendations. | lld:pubmed |
pubmed-article:21301335 | pubmed:language | eng | lld:pubmed |
pubmed-article:21301335 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:21301335 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:21301335 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:21301335 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:21301335 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:21301335 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:21301335 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:21301335 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:21301335 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:21301335 | pubmed:month | Apr | lld:pubmed |
pubmed-article:21301335 | pubmed:issn | 1535-3877 | lld:pubmed |
pubmed-article:21301335 | pubmed:author | pubmed-author:RoilidesEmman... | lld:pubmed |
pubmed-article:21301335 | pubmed:author | pubmed-author:SharlandMikeM | lld:pubmed |
pubmed-article:21301335 | pubmed:author | pubmed-author:TurkovaAnnaA | lld:pubmed |
pubmed-article:21301335 | pubmed:issnType | Electronic | lld:pubmed |
pubmed-article:21301335 | pubmed:volume | 24 | lld:pubmed |
pubmed-article:21301335 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:21301335 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:21301335 | pubmed:pagination | 163-71 | lld:pubmed |
pubmed-article:21301335 | pubmed:meshHeading | pubmed-meshheading:21301335... | lld:pubmed |
pubmed-article:21301335 | pubmed:meshHeading | pubmed-meshheading:21301335... | lld:pubmed |
pubmed-article:21301335 | pubmed:meshHeading | pubmed-meshheading:21301335... | lld:pubmed |
pubmed-article:21301335 | pubmed:meshHeading | pubmed-meshheading:21301335... | lld:pubmed |
pubmed-article:21301335 | pubmed:meshHeading | pubmed-meshheading:21301335... | lld:pubmed |
pubmed-article:21301335 | pubmed:meshHeading | pubmed-meshheading:21301335... | lld:pubmed |
pubmed-article:21301335 | pubmed:meshHeading | pubmed-meshheading:21301335... | lld:pubmed |
pubmed-article:21301335 | pubmed:meshHeading | pubmed-meshheading:21301335... | lld:pubmed |
pubmed-article:21301335 | pubmed:meshHeading | pubmed-meshheading:21301335... | lld:pubmed |
pubmed-article:21301335 | pubmed:year | 2011 | lld:pubmed |
pubmed-article:21301335 | pubmed:articleTitle | Amphotericin B in neonates: deoxycholate or lipid formulation as first-line therapy - is there a 'right' choice? | lld:pubmed |
pubmed-article:21301335 | pubmed:affiliation | Paediatric Infectious Diseases Unit, St George's Hospital, London, UK. | lld:pubmed |
pubmed-article:21301335 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:21301335 | pubmed:publicationType | Review | lld:pubmed |